Phase 1 Trial of Dose Escalated BGB324 in Combination With Docetaxel for Previously Treated Advanced Non-small Cell Lung Cancer (NSCLC)
Phase of Trial: Phase I
Latest Information Update: 22 Mar 2017
At a glance
- Drugs BGB 324 (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 22 Nov 2016 Planned End Date changed from 1 Nov 2019 to 1 Nov 2020.
- 22 Nov 2016 Status changed from not yet recruiting to recruiting.
- 02 Oct 2016 Status changed from planning to not yet recruiting.